Prothena Corp Public (PRTA) Interest Expenses (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Interest Expenses came in at $800000.0 in Q1 2026, up 14.29% year-on-year from $700000.0 in Q1 2025, and little changed quarter-over-quarter from $800000.0 in Q4 2025.
Prothena Corp Public (PRTA) Interest Expenses (2012 - 2026) Analysis & Trends
Prothena Corp Public's Interest Expenses history runs 15 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- On a quarterly basis, Interest Expenses rose 14.29% year-over-year to $800000.0 in Q1 2026; TTM through Mar 2026 was $3.1 million, a 10.71% increase from a year earlier, with the FY2025 full-year figure at $266.6 million, up 34.05% from the prior year.
- Interest Expenses steadied at $800000.0 in Q1 2026 per PRTA's latest filing, from $800000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $10.8 million in Q2 2025 and bottomed at -$4.5 million in Q4 2023.
- The 5-year median for Interest Expenses is $800000.0 (2025), against an average of $1.4 million.
- Across the five-year window, Interest Expenses sank 381.25% in 2023 and jumped 1438.71% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $1.6 million in 2022, then sank by 381.25% to -$4.5 million in 2023, then surged by 115.56% to $700000.0 in 2024, then rose by 14.29% to $800000.0 in 2025, then changed by 0.0% to $800000.0 in 2026.
- Per Business Quant, the three latest PRTA Interest Expenses figures stand at $800000.0 (Q1 2026), $800000.0 (Q4 2025), and $800000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Prothena Corp Public | 467.80 Mn | 138.33 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 10.77 Mn |
| Jun 30, 2025 | 10.77 Mn |
| Mar 31, 2025 | 700,000.00 |
| Mar 31, 2025 | 700,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | -4.50 Mn |
| Dec 31, 2023 | -4.50 Mn |